Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Cash flows from operating activities:
Net loss			$ (64,842,000)	$ (98,218,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	$ 787,000	$ 1,100,000	1,609,000	2,131,000
Stock-based compensation expense			13,111,000	14,028,000
In-process research and development expenses	7,500,000	22,500,000	7,500,000	22,500,000
Accretion on marketable securities, net			(3,485,000)	(4,719,000)
Impairment charge on operating lease assets and property and equipment				4,653,000
Impairment charge on investment in equity securities				402,000
Changes in operating assets and liabilities:
Prepaid expenses and other current and long-term assets			516,000	(840,000)
Accounts payable			1,195,000	(77,000)
Accrued expenses and other current and long-term liabilities			(6,628,000)	(2,313,000)
Operating lease assets and liabilities, net			(1,062,000)	19,000
Net cash used in operating activities			(52,086,000)	(62,434,000)
Cash flows from investing activities:
Purchases of marketable securities			(67,204,000)	(144,333,000)
Maturities of marketable securities			122,827,000	90,250,000
In-process research and development			(5,500,000)	(22,500,000)
Purchases of property and equipment			(113,000)	(55,000)
Net cash provided by (used in) investing activities			50,010,000	(76,638,000)
Cash flows from financing activities:
Proceeds from issuance of common stock in private placement, net of fees and expenses				43,637,000
Proceeds from issuance of common stock in underwritten offering, net of discounts and offering costs				174,638,000
Proceeds from the exercise of stock options			76,000	129,000
Proceeds from issuance of common stock under the Employee Stock Purchase Plan			404,000	395,000
Net cash provided by financing activities			480,000	218,799,000
Net (decrease) increase in cash, cash equivalents and restricted cash			(1,596,000)	79,727,000
Cash, cash equivalents and restricted cash at beginning of the period			68,147,000	93,483,000	$ 93,483,000
Cash, cash equivalents and restricted cash at end of the period	$ 66,551,000	$ 173,210,000	66,551,000	173,210,000	$ 68,147,000
Supplemental disclosure of noncash investing and financing activities:
Amounts accrued for in-process research and development			$ 2,000,000
Vesting of early exercised options				310,000
Amounts accrued for offering costs				245,000
Amounts accrued for deferred offering costs				170,000
Obligation accrued for investment in equity securities				$ 235,000